Drug Trial Radar · NCT05997927
Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jul 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Jul 20, 2023
Primary completion
Jul 9, 2024
Study completion Jul 9, 2024
Sponsor
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Aug 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.
Conditions
- Moderate to Severe Atopic Dermatitis
Interventions
VC005 tabletsDrug
VC005 groups repeat administration for 12 weeks
VC005 Tablets PlaceboDrug
VC005 placebo groups repeat administration for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change from baseline in EASI scoreTime frame: week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences Hospital for Skin Diseases
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.